Egle Ramelyte

Zurich, ZH 8032, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study.

Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study.

Journal: Current oncology (Toronto, Ont.)

Published: May 27, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Journal: Current oncology (Toronto, Ont.)

Published: February 26, 2026

Safety of Multi-Omics-Guided Therapy in Advanced Melanoma: A Matched Comparative Cohort Analysis.

Safety of Multi-Omics-Guided Therapy in Advanced Melanoma: A Matched Comparative Cohort Analysis.

Journal: JCO precision oncology

Published: February 25, 2026

Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.

Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.

Journal: Medicina (Kaunas, Lithuania)

Published: January 30, 2026

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes.

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes.

Journal: Journal of cutaneous pathology

Published: December 15, 2025

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 28, 2025

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

Journal: Nature medicine

Published: November 17, 2025

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data.

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data.

Journal: Cancers

Published: November 16, 2025

Escalation and de-escalation of therapy for high-risk melanomas

Escalation and de-escalation of therapy for high-risk melanomas

Journal: Therapeutische Umschau. Revue therapeutique

Published: October 01, 2025

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project.

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project.

Journal: NPJ precision oncology

Published: July 21, 2025

First-in-human e-Flash radiotherapy using a modified conventional C-arm linear accelerator.

First-in-human e-Flash radiotherapy using a modified conventional C-arm linear accelerator.

Journal: Clinical and translational radiation oncology

Published: July 18, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026